US Bancorp DE Has $132.10 Million Stock Position in Pfizer Inc. (NYSE:PFE)

Key Points

• US Bancorp DE reduced its stake in Pfizer Inc. by 9.8%, holding 5,213,250 shares valued at approximately $132.1 million after selling 563,335 shares in the first quarter.
• A study of analysts shows a mixed outlook, with most assigning a "neutral" rating and price targets generally ranging from $24.00 to $28.28 for Pfizer's stock.
• Pfizer recently declared a quarterly dividend of $0.43 per share, resulting in an annualized yield of 7.3% despite a payout ratio exceeding 124%.

US Bancorp DE decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 9.8% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 5,213,250 shares of the biopharmaceutical company's stock after selling 563,335 shares during the quarter. US Bancorp DE owned approximately 0.09% of Pfizer worth $132,104,000 as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Brighton Jones LLC increased its position in Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC increased its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after acquiring an additional 2,087 shares during the period. Cinctive Capital Management LP increased its position in Pfizer by 7.1% during the fourth quarter. Cinctive Capital Management LP now owns 181,302 shares of the biopharmaceutical company's stock worth $4,810,000 after acquiring an additional 12,060 shares during the period. OneAscent Financial Services LLC increased its position in Pfizer by 44.8% during the fourth quarter. OneAscent Financial Services LLC now owns 36,999 shares of the biopharmaceutical company's stock worth $982,000 after acquiring an additional 11,447 shares during the period. Finally, Westpac Banking Corp increased its position in Pfizer by 38.4% during the fourth quarter. Westpac Banking Corp now owns 102,671 shares of the biopharmaceutical company's stock worth $2,724,000 after acquiring an additional 28,473 shares during the period. Institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Bank of America boosted their target price on shares of Pfizer from $26.00 to $27.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 target price on the stock. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating on the stock in a report on Wednesday, April 30th. Citigroup boosted their price target on shares of Pfizer from $23.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group boosted their price target on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $28.28.

Pfizer Price Performance

Shares of PFE traded up $0.20 during trading hours on Friday, hitting $23.49. The stock had a trading volume of 51,287,529 shares, compared to its average volume of 38,018,180. The company's fifty day moving average is $24.36 and its two-hundred day moving average is $24.58. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $31.32. The stock has a market capitalization of $133.55 billion, a price-to-earnings ratio of 17.02, a P/E/G ratio of 0.84 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the firm earned $0.82 EPS. The firm's quarterly revenue was down 7.8% compared to the same quarter last year. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.3%. Pfizer's dividend payout ratio is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.